Practical aspects of including functional endpoints in developmental toxicity studies. Case study: Immune function in HuCD4 transgenic mice exposed to anti-CD4 MAb in utero

Human and Experimental Toxicology

Volumn 21, Issue 9-10, 2002, Pages 507-512

  Herzyk, Danuta J ^a   Bugelski, P J ^a   Hart, T K ^a   Wier, P J ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Anti CD4 antibody; C. albicans infection; Lymphoid tissues; Offspring transgenic mice

Indexed keywords

CD4 ANTIGEN; CHIMERIC ANTIBODY; KELIXIMAB; MONOCLONAL ANTIBODY; PRIMATIZED;

ANIMAL EXPERIMENT; ANTIBODY SPECIFICITY; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CASE STUDY; CONTROLLED STUDY; ENVIRONMENTAL EXPOSURE; FEMALE; FETOTOXICITY; FETUS; FETUS DEVELOPMENT; GROWTH PERIOD; HOST RESISTANCE; IMMUNOTOXICITY; LACTATION; LYMPHOCYTE SUBPOPULATION; LYMPHOID TISSUE; MORPHOLOGY; MOUSE; NEWBORN; NONHUMAN; POSTNATAL DEVELOPMENT; PRACTICE GUIDELINE; PREGNANCY; PRENATAL DEVELOPMENT; PRIORITY JOURNAL; PROGENY; REPRODUCTION; REPRODUCTIVE TOXICITY; SAFETY; SPECIES DIFFERENCE; TOXICOLOGY; TRANSGENIC MOUSE;

AGE FACTORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; ANTIGENS, CD4; CANDIDIASIS; DISEASE MODELS, ANIMAL; FEMALE; IMMUNE SYSTEM; IMMUNITY, CELLULAR; LYMPHOCYTE COUNT; MALE; MICE; MICE, TRANSGENIC; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RISK ASSESSMENT; TERATOGENS; TOXICITY TESTS; TOXICOLOGY;

ANIMALIA; CANDIDA; CANDIDA ALBICANS; MACACA FASCICULARIS; MUS MUSCULUS; PAN TROGLODYTES;

EID: 0036760252     PISSN: 09603271     EISSN: None     Source Type: Journal    
DOI: 10.1191/0960327102ht289oa     Document Type: Article

References (17)

1. Ellmeier W, Sawada S, Littman DR. The regulation of CD4 and CD8 coreceptor gene expression during T cell development. Annu Rev Immunol 1999; 17: 523-54.
2. Choy EH, Kingsley GH, Panayi GS. Anti-CD4 monoclonal antibodies in rheumatoid arthritis. Springer Semin Immunopathol 1998; 20: 261-73.
3. Kon OM, Kay AB. T cells and chronic asthma. Int Arch Allergy Immunol 1999; 118: 133-35.
4. + T cells in chimpanzees: in vitro and in vivo: characterization of a MAb (IDEC-CE9.1) to human CD4. Clin Immunol Immunopathol 1997; 84: 73-84.
5. Killeen N, Sawada S, Littman DR. Regulated expression of human CD4 rescues helper T cell development in mice lacking expression of endogenous CD4. EMBO J 1993; 12: 1547-53.
6. ICH Reference: US Food and Drug Administration. International conference on harmonisation; Guideline on detection of toxicology to reproduction for medicinal products; Availability. Federal Register 1994; Vol. 59, No. 183, pp. 48746-52. See also Amendment, Federal Register 1996; Vol. 61, No. 67, pp. 15359-61.
7. Bugelski PJ, Herzyk DJ, Rehm S, et al. Preclinical development of Keliximab, a primatized anti-CD4 monoclonal antibody, in human CD4 transgenic mice: characterization of the model and safety studies. Hum Exp Toxicol 2000; 19: 230-43.
8. Zuniga-Pflucker JC, McCarthy SA, Weston M, Longo DL, Singer A, Kruisbeek AM. Role of CD4 in thymocyte selection and maturation. J Exp Med 1989; 169: 2085-96.
9. Miller RK, Koszalka TR, Brent RL. The transport of molecules across placental membranes. In Poste G, Nicolson GL eds. The cell surface in animal embryogenesis and development. Amsterdam: Elsevier/North-Holland Biomedical Press, 1976: 145-223.
10. Herzyk DJ, GoreER, Polsky R, et al. Immunomodulatory effects of anti-CD4 antibody in host resistance against infections and tumors in human CD4 transgenic mice. Infect Immun 2001; 69: 1032-43.
11. Sharma A, Davis CB, Tobia LP, et al. Comparative pharmacodynamics of keliximab and clenoliximab in transgenic mice bearing human CD4. J Pharmacol Exp Ther 2000; 293: 33-41.
12. Wier PJ, Guerriero FJ, Walker RF. Implementation of a primary screen for developmental neurotoxicity. Fundam Appl Toxicol 1989; 13: 118-36.
13. Gossett KA, Narayanan PK, Williams DM, et al. Flow cytometry in the preclinical development of biopharmaceuticals. Toxicol Pathol 1999; 27: 32-37.
14. Herzyk DJ, Ruggieri EV, Cunningham L, et al. Single-organism model of host defense against infection: a novel immunotoxicologic approach to evaluate immunomodulatory drugs. Toxicol Pathol 1997; 25: 351-62.
15. Cammarota G, Scheirle A, Takacs B, et al. Identification of a CD4 binding site on the beta 2 domain of HLA-DR molecules. Nature 1992; 356: 799-801.
16. Clayton LK, Sieh M, Pious DA, Reinherz EL. Identification of human CD4 residues affecting class II MHC versus HIV-1 gp120 binding. Nature 1989; 339: 548-51.
17. Fleming AL, Field EH, Tolaymat N, Cowdery JS. Age influences recovery of systemic and mucosal immune responses following acute depletion of CD4 T cells. Clin Immunol Immunopharmacol 1993; 69: 285-91.